Journal
BIOMARKER RESEARCH
Volume 10, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40364-022-00385-1
Keywords
Claudin18; 2; Molecular biomarker; Immunotherapy; Monoclonal antibody (mAb); Bispecific antibody (BsAb); Chimeric antigen receptor T (CAR-T) cells; Antibody-drug conjugates (ADCs); Clinical trial
Categories
Funding
- Project of Henan Provincial Education Department, China [20A320062]
- Project of Science and Technology Department of Henan Province, China [LHGJ20190039, SBGJ20202076]
- Talent Research Fund of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Ask authors/readers for more resources
CLDN18.2 protein, with limited expression in normal tissues and often abnormal expression in various primary malignant tumors, has become a potential specific marker for diagnosis and treatment of these tumors. Immunotherapy strategies targeting CLDN18.2, such as monoclonal antibodies, bispecific antibodies, CAR-T cells, and ADCs, have shown promising advancements in recent studies.
The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18.2, have been developed. In this review, we outline recent advances in the development of immunotherapy strategies targeting CLDN18.2, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), chimeric antigen receptor T (CAR-T) cells redirected to target CLDN18.2, and antibody-drug conjugates (ADCs).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available